Brian Park, PharmD

Brian Park, PharmD

Drug Information Specialist
Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Symdeko Approved to Treat Younger Cystic Fibrosis Patients

The Food and Drug Administration (FDA) has approved Symdeko (tezacaftor/ivacaftor and ivacaftor; Vertex Pharmaceuticals) for the treatment of patients aged ≥6 years with cystic fibrosis (CF) who are homozygous for the F508del mutation or who have at least 1 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor. Previously,…

Opdivo Evaluated as First Line Tx in Unresectable Hepatocellular Carcinoma Trial

Bristol-Myers Squibb announced topline results from the CheckMate-459 phase 3 trial of Opdivo (nivolumab) as first line treatment in patients with unresectable hepatocellular carcinoma (HCC). The CheckMate-459 trial was a multicenter, open label, randomized study that evaluated the efficacy of Opdivo compared with sorafenib in patients with unresectable HCC. Patients were treated until disease progression…